111 related articles for article (PubMed ID: 18284634)
1. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
[TBL] [Abstract][Full Text] [Related]
2. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma.
Fernández RM; Peciña A; Antiñolo G; Navarro E; Borrego S
Thyroid; 2006 Apr; 16(4):411-7. PubMed ID: 16646689
[TBL] [Abstract][Full Text] [Related]
3. Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma.
Ruiz-Llorente S; Montero-Conde C; Milne RL; Moya CM; Cebrián A; Letón R; Cascón A; Mercadillo F; Landa I; Borrego S; Pérez de Nanclares G; Alvarez-Escolá C; Díaz-Pérez JA; Carracedo A; Urioste M; González-Neira A; Benítez J; Santisteban P; Dopazo J; Ponder BA; Robledo M;
Cancer Res; 2007 Oct; 67(19):9561-7. PubMed ID: 17909067
[TBL] [Abstract][Full Text] [Related]
4. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?
Cardot-Bauters C; Leteurtre E; Leclerc L; Vantyghem MC; Do Cao C; Wemeau JL; d'Herbomez M; Carnaille B; Barbu V; Pinson S; Pigny P;
Clin Endocrinol (Oxf); 2008 Sep; 69(3):506-10. PubMed ID: 18331611
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.
Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H
Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
[TBL] [Abstract][Full Text] [Related]
7. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
[TBL] [Abstract][Full Text] [Related]
8. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.
Cebrian A; Lesueur F; Martin S; Leyland J; Ahmed S; Luccarini C; Smith PL; Luben R; Whittaker J; Pharoah PD; Dunning AM; Ponder BA
J Clin Endocrinol Metab; 2005 Nov; 90(11):6268-74. PubMed ID: 16091499
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms Within the
Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R
Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166
[No Abstract] [Full Text] [Related]
11. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.
Muzza M; Cordella D; Bombled J; Bressac-de Paillerets B; Guizzardi F; Francis Z; Beck-Peccoz P; Schlumberger M; Persani L; Fugazzola L
Eur J Endocrinol; 2010 Apr; 162(4):771-7. PubMed ID: 20103606
[TBL] [Abstract][Full Text] [Related]
12. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?
Baumgartner-Parzer SM; Lang R; Wagner L; Heinze G; Niederle B; Kaserer K; Waldhäusl W; Vierhapper H
J Clin Endocrinol Metab; 2005 Nov; 90(11):6232-6. PubMed ID: 16118333
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation.
Tamanaha R; Camacho CP; Pereira AC; da Silva AM; Maciel RM; Cerutti JM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):56-64. PubMed ID: 19138318
[TBL] [Abstract][Full Text] [Related]
15. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
[TBL] [Abstract][Full Text] [Related]
16. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
[TBL] [Abstract][Full Text] [Related]
17. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer.
Borrego S; Fernández RM; Dziema H; Japón MA; Marcos I; Eng C; Antiñolo G
Thyroid; 2002 Nov; 12(11):1017-22. PubMed ID: 12490080
[TBL] [Abstract][Full Text] [Related]
19. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S
Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
